{"id":"d706b4c0-0165-51f7-b397-417b2251e897","stable_key":"31b1baa4-4113-5541-b9e7-fe44a5253a07:eae-50","predicate":"no_detected_change_in_recorded_experiment","statement":"SA at 50 mg/kg showed no significant improvement in the EAE behavioral comparison.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"c6ca47a6-3b8e-5b31-bd07-307b9833d63d","mechanism_event_label":"SA at 50 mg/kg showed no significant improvement in the EAE behavioral comparison.","subject":{"id":"67ad4a8f-1bf6-59e5-90a6-97b7709024d3","slug":"shikimic-acid","display_name":"Shikimic acid","entity_type_key":"small_molecule"},"object":{"id":"00826b72-2cb3-5aa8-ba90-f0cbad85deb8","slug":"mouse-eae-score","display_name":"Mouse EAE behavioral score","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"c6ca47a6-3b8e-5b31-bd07-307b9833d63d","stable_key":"31b1baa4-4113-5541-b9e7-fe44a5253a07:eae-50-event","event_type":"experimental_observation","label":"SA at 50 mg/kg showed no significant improvement in the EAE behavioral comparison.","description":"**Repair and injury prevention separated in time.** In the mouse focal lysolecithin model, shikimic acid groups did not have a smaller demyelinated region at day 7, but 100–200 mg/kg groups had less demyelination and more mature-oligodendrocyte staining at day 14. The article also reported improvement in EAE scores at 100–200 mg/kg, with a 50-mg/kg behavioral null. These model/time-dependent observations do not establish treatment of human multiple sclerosis. [Shikimic Acid Promotes Oligodendrocyte Precursor Cell Differentiation and Accelerates Remyelination in Mice.](https://pubmed.ncbi.nlm.nih.gov/30684125/)","status":"provisional","compartment":null,"participants":[{"entity":{"id":"67ad4a8f-1bf6-59e5-90a6-97b7709024d3","slug":"shikimic-acid","display_name":"Shikimic acid","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"SA 50 mg/kg","sequence_order":0,"notes":""},{"entity":{"id":"00826b72-2cb3-5aa8-ba90-f0cbad85deb8","slug":"mouse-eae-score","display_name":"Mouse EAE behavioral score","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"no_detected_change","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text retrieved; relevant methods/results/figures reviewed. Selective extraction, not raw-data reanalysis or exhaustive supplemental extraction.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"SA 50 mg/kg\", \"comparator\": \"EAE vehicle\", \"endpoint\": \"SA at 50 mg/kg showed no significant improvement in the EAE behavioral comparison.\", \"effect_direction\": \"no_detected_change\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; source-derived draft.","entity":null},{"dimension":"experimental_model","value_text":"Mouse EAE model, dose-specific observation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"SA at 50 mg/kg showed no significant improvement in the EAE behavioral comparison.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Shikimic Acid Promotes Oligodendrocyte Precursor Cell Differentiation and Accelerates Remyelination in Mice. | 2019 | DOI 10.1007/s12264-018-0322-7 | PMID 30684125 | https://pubmed.ncbi.nlm.nih.gov/30684125/ | https://doi.org/10.1007/s12264-018-0322-7 | https://pmc.ncbi.nlm.nih.gov/articles/PMC6527532/","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference lines 73-73; exact primary location described in quoted passage where extracted.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"c0d75cdc-3cc7-5313-bec2-07bc2fcbaaef","evidence_kind":"source_excerpt","locator":"Lines 73-73","start_line":73,"end_line":73,"excerpt":"**Repair and injury prevention separated in time.** In the mouse focal lysolecithin model, shikimic acid groups did not have a smaller demyelinated region at day 7, but 100–200 mg/kg groups had less demyelination and more mature-oligodendrocyte staining at day 14. The article also reported improvement in EAE scores at 100–200 mg/kg, with a 50-mg/kg behavioral null. These model/time-dependent observations do not establish treatment of human multiple sclerosis. [Shikimic Acid Promotes Oligodendrocyte Precursor Cell Differentiation and Accelerates Remyelination in Mice.](https://pubmed.ncbi.nlm.nih.gov/30684125/)","model_system":"Mouse EAE model, dose-specific observation.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Exact excerpt of the retained AI-assisted reviewed reference; primary sources are cited in primary_references and access scope is retained. Not a verbatim quotation from a primary paper.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"e6ae59de-0369-5c2f-8262-57d91302671c","stable_key":"import-31b1baa4-4113-5541-b9e7-fe44a5253a07","title":"Shikimic acid: detailed mechanisms of action (reviewed 5 October 2026)","document_type":"imported_text","citation_label":"Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication.","file_path":"","sha256":"95b1f9e9577661312d67f36e156d2e49326b207f296c1c0e801a5b007fd8e283","revision_id":"cd3237f1-131a-557d-84b5-7543259807b0","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}